Missed Nvidia? Buy Elon Musk’s “Silent Partner”

In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my favorite stocks. Today, it’s probably the most popular stock in the world. I believe this Elon Musk “silent partner” could be the next big AI winner.

So please click here to see the details because a lot of people could get rich.

Frank Clyburn Biography and Net Worth

EVP of Merck & Co., Inc.

Frank Clyburn is executive vice president and president of Human Health for Merck. He is responsible for all Human Health marketing and commercial operations globally and the P&L for the company’s portfolio of medicines and vaccines.

Prior to this role, Frank was chief commercial officer for Merck, responsible for Human Health commercial operations and the Human Health P&L. From 2013 to 2018, Frank was the inaugural president of the company’s global oncology business. He led the creation of this fully integrated global business unit, the worldwide launch of Merck’s immuno-oncology medicine and the establishment of Merck as a leader in oncology.

Previously, he was the president of the primary care and women’s health businesses and market access function. He also led the company’s global pharmaceutical franchises and lived in Shanghai and Lucerne. Frank joined the company in 2008 to lead its biologics business.

Before joining Merck, Frank was vice president of the oncology and internal medicine business units at Sanofi Aventis and held a wide range of leadership roles with that company, in addition to leading the integration of Sanofi and Aventis.

Frank received his Master of Business Administration degree from Arizona State University and his Bachelor of Arts degree from Franklin & Marshall College. He currently serves on the board of directors for the European Federation of Pharmaceutical Industries and Associations (EFPIA) and DuPont. Frank also served as chairman to the Thomas Edison State University board of trustees.

What is Frank Clyburn's net worth?: The estimated net worth of Frank Clyburn is at least $9.77 million as of August 5th, 2020. Mr. Clyburn owns 99,639 shares of Merck & Co., Inc. stock worth more than $9,769,604 as of December 21st. This net worth evaluation does not reflect any other assets that Mr. Clyburn may own. Learn More about Frank Clyburn's net worth.
How do I contact Frank Clyburn?: The corporate mailing address for Mr. Clyburn and other Merck & Co., Inc. executives is 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033. Merck & Co., Inc. can also be reached via phone at (908) 740-4000 and via email at [email protected]. Learn More on Frank Clyburn's contact information.
Has Frank Clyburn been buying or selling shares of Merck & Co., Inc.?: Frank Clyburn has not been actively trading shares of Merck & Co., Inc. within the last three months. Most recently, Frank Clyburn sold 39,762 shares of the business's stock in a transaction on Monday, November 1st. The shares were sold at an average price of $87.87, for a transaction totalling $3,493,886.94. Learn More on Frank Clyburn's trading history.
Who are Merck & Co., Inc.'s active insiders?: Merck & Co., Inc.'s insider roster includes Sanat Chattopadhyay (Insider), Frank Clyburn (EVP), Robert Davis (CFO), Richard Deluca (EVP), Kenneth Frazier (Insider), Julie Gerberding (EVP), Clark Golestani (EVP), Michael Holston (EVP), Rita Karachun (VP), Caroline Litchfield (CFO), Steven Mizell (EVP), Johannes Oosthuizen (Insider), Joseph Romanelli (Insider), Ashley Watson (SVP), and Wendell Weeks (Director). Learn More on Merck & Co., Inc.'s active insiders.
Are insiders buying or selling shares of Merck & Co., Inc.?: During the last year, insiders at the sold shares 2 times. They sold a total of 51,694 shares worth more than $6,545,285.10. The most recent insider tranaction occured on February, 13th when insider Joseph Romanelli sold 1,000 shares worth more than $124,890.00. Insiders at Merck & Co., Inc. own 0.1% of the company. Learn More about insider trades at Merck & Co., Inc..
Information on this page was last updated on 2/13/2024.

Frank Clyburn Insider Trading History at Merck & Co., Inc.

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/1/2021	Sell	39,762	$87.87	$3,493,886.94
5/10/2021	Sell	19,324	$78.32	$1,513,455.68
8/5/2020	Sell	18,876	$81.55	$1,539,337.80	99,639
5/7/2019	Sell	25,000	$77.73	$1,943,250.00	92,604

Frank Clyburn Buying and Selling Activity at Merck & Co., Inc.

Merck & Co., Inc. Company Overview

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians, wholesalers, government entities, veterinarians, distributors, animal producers, farmers, and pet owners. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.

Today's Range

Now: $98.05

$97.90

$99.68

50 Day Range

MA: $102.25

$96.30

$111.54

2 Week Range

Now: $98.05

$94.48

$134.63

Volume

29,272,893 shs

Average Volume

9,418,368 shs

Market Capitalization

$248.03 billion

P/E Ratio

20.56

Dividend Yield

3.02%

Beta

0.39

Did You See Trump’s Bombshell Exec. Order 001?

From Banyan Hill Publishing | Ad

Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minutes of stepping into the Oval Office...

I put all the details together for you here — but please hurry.